Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
Atherosclerosis is the primary cause of cardiovascular diseases, such as myocardial infarction and stroke, which account for the highest death toll worldwide. Macrophage is the major contributor to atherosclerosis progression, and therefore, macrophage-associated pathological process is considered a...
Main Authors: | Ping Ping Hu, Shuang Xue Luo, Xiao Qing Fan, Di Li, Xiao Yong Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1000316/full |
Similar Items
-
Ocular Nanomedicine
by: Zhimin Tang, et al.
Published: (2022-05-01) -
Nanomedicine for Diagnosis and Treatment of Atherosclerosis
by: Jingyun Cheng, et al.
Published: (2023-12-01) -
Editorial: Advances on targeted nanomedicines for atherosclerosis
by: Qinggong Han, et al.
Published: (2022-10-01) -
Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque in ApoE(−/−) mice
by: Qi Wang, et al.
Published: (2021-07-01) -
Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis
by: Linsey J. F. Peters, et al.
Published: (2021-07-01)